propranolol has been researched along with Cardiac Remodeling, Ventricular in 20 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "193 patients with their first non-Q-wave myocardial infarction (NQMI) were examined with the aim of studying the functional features of NQMI and estimate the influence of pre-hospital treatment with propranalol (PP), heparin and aspirin." | 7.73 | [Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease]. ( Baltabaev, TB; Beĭshenkulov, MT; Kudaĭbergenova, NT, 2005) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 7.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "The effects of propranolol and verapamil on contractile dysfunction, subcellular remodeling and changes in gene expression in cardiac hypertrophy due to pressure overload were examined." | 7.70 | Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil. ( Dhalla, NS; Elmoselhi, AB; Goel, R; Sentex, E; Takeo, S; Wang, J, 2000) |
| "Insulin resistance was induced by HFrHFD feeding for 16 weeks." | 5.62 | Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2021) |
| "In propranolol-treated rats, hypertrophy of the LV septum, papillary muscle, and right ventricle were similar to those of the infarcted control." | 5.31 | Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. ( Bonnefont-Rousselot, D; Komajda, M; Lechat, P; Mansuy, P; Mougenot, N; Raillecove, F; Ramirez-Gil, JF, 2000) |
| " We compared the data from 8 infants with severe congestive heart failure due to left-to-right shunts, who received digoxin and diuretics alone, to 9 infants who received additional treatment with propranolol." | 5.10 | Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. ( Buchhorn, R; Fielitz, J; Hetzer, R; Hulpke-Wette, M; Pregla, R; Regitz-Zagrosek, V; Ross, RD; Ruschewski, W, 2003) |
| " A rat model of thyrotoxicosis was established by daily intraperitoneal injections of L-thyroxine (T(4), 100 μg/kg) for 4 weeks." | 3.78 | Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy. ( Cho, KI; Choi, BG; Jeon, YK; Kang, JH; Kim, BH; Kim, IJ; Kim, JY; Kim, SJ; Kim, SM; Kim, SS; Kim, YK, 2012) |
| " Three weeks after inducing myocardial infarction (MI), rats were treated daily with or without 20 and 75 mg/kg atenolol, a selective β(1) -AR antagonist, or propranolol, a non-selective β-AR antagonist, for 5 weeks." | 3.77 | β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure. ( Dhalla, NS; Elimban, V; Machackova, J; Sanganalmath, SK, 2011) |
| "193 patients with their first non-Q-wave myocardial infarction (NQMI) were examined with the aim of studying the functional features of NQMI and estimate the influence of pre-hospital treatment with propranalol (PP), heparin and aspirin." | 3.73 | [Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease]. ( Baltabaev, TB; Beĭshenkulov, MT; Kudaĭbergenova, NT, 2005) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 3.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "The effects of propranolol and verapamil on contractile dysfunction, subcellular remodeling and changes in gene expression in cardiac hypertrophy due to pressure overload were examined." | 3.70 | Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil. ( Dhalla, NS; Elmoselhi, AB; Goel, R; Sentex, E; Takeo, S; Wang, J, 2000) |
| "To investigate the effects of perindopril, propranolol, and dihydrochlorothiazide on artery wall thickening, left ventricular hypertrophy, and cardiac fibrosis in spontaneously hypertensive rats (SHR)." | 3.70 | Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats. ( Chen, DG; Chen, SC; Rui, HB; Su, JZ; Wang, HJ; Wang, XY; Wu, KG, 1999) |
| "Insulin resistance was induced by HFrHFD feeding for 16 weeks." | 1.62 | Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2021) |
| "Propranolol treatment normalized also the prolongation of the action potential in papillary muscles from the diabetic rat hearts." | 1.37 | Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca2+ signaling in rat. ( Tuncay, E; Turan, B; Zeydanli, EN, 2011) |
| "The role of the adrenergic system on ventricular remodeling induced by cigarette smoking is unknown." | 1.35 | Effects of the administration of beta-blockers on ventricular remodeling induced by cigarette smoking in rats. ( Azevedo, PS; Campana, AO; Duarte, DR; Matsubara, BB; Matsubara, LS; Minicucci, MF; Oliveira, LC; Paiva, SA; Zornoff, LA, 2009) |
| "Propranolol treatment of TOT mice reversed the alterations in SERCA and NCX protein levels but not potassium channels." | 1.32 | Calcium dynamics in the failing heart: restoration by beta-adrenergic receptor blockade. ( Benkusky, N; Fiset, C; Glascock, B; Lalli, MJ; Periasamy, M; Plank, DM; Ritsu, H; Sussman, MA; Valdivia, HH; Witt, S; Yatani, A, 2003) |
| "In propranolol-treated rats, hypertrophy of the LV septum, papillary muscle, and right ventricle were similar to those of the infarcted control." | 1.31 | Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. ( Bonnefont-Rousselot, D; Komajda, M; Lechat, P; Mansuy, P; Mougenot, N; Raillecove, F; Ramirez-Gil, JF, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, WS | 1 |
| Ahmed, HMS | 1 |
| Mahmoud, AAA | 1 |
| Mahmoud, MF | 1 |
| Ibrahim, IAAE | 1 |
| Duarte, DR | 1 |
| Oliveira, LC | 1 |
| Minicucci, MF | 1 |
| Azevedo, PS | 1 |
| Matsubara, BB | 1 |
| Matsubara, LS | 1 |
| Campana, AO | 1 |
| Paiva, SA | 1 |
| Zornoff, LA | 1 |
| Machackova, J | 2 |
| Sanganalmath, SK | 2 |
| Barta, J | 1 |
| Dhalla, KS | 1 |
| Dhalla, NS | 3 |
| Elimban, V | 1 |
| Chen, WQ | 1 |
| Cai, H | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Zhang, Y | 1 |
| O-Uchi, J | 1 |
| Lopes, CM | 1 |
| Guo, D | 1 |
| Kassiri, Z | 1 |
| Basu, R | 1 |
| Chow, FL | 1 |
| Kandalam, V | 1 |
| Damilano, F | 1 |
| Liang, W | 1 |
| Izumo, S | 1 |
| Hirsch, E | 1 |
| Penninger, JM | 1 |
| Backx, PH | 1 |
| Oudit, GY | 1 |
| Tuncay, E | 1 |
| Zeydanli, EN | 1 |
| Turan, B | 1 |
| Kim, BH | 1 |
| Cho, KI | 1 |
| Kim, SM | 1 |
| Kim, JY | 1 |
| Choi, BG | 1 |
| Kang, JH | 1 |
| Jeon, YK | 1 |
| Kim, SS | 1 |
| Kim, SJ | 1 |
| Kim, YK | 1 |
| Kim, IJ | 1 |
| Plank, DM | 1 |
| Yatani, A | 1 |
| Ritsu, H | 1 |
| Witt, S | 1 |
| Glascock, B | 1 |
| Lalli, MJ | 1 |
| Periasamy, M | 1 |
| Fiset, C | 1 |
| Benkusky, N | 1 |
| Valdivia, HH | 1 |
| Sussman, MA | 1 |
| Buchhorn, R | 1 |
| Hulpke-Wette, M | 1 |
| Ruschewski, W | 1 |
| Ross, RD | 1 |
| Fielitz, J | 1 |
| Pregla, R | 1 |
| Hetzer, R | 1 |
| Regitz-Zagrosek, V | 1 |
| Marano, G | 1 |
| Palazzesi, S | 1 |
| Vergari, A | 1 |
| Catalano, L | 1 |
| Gaudi, S | 1 |
| Testa, C | 1 |
| Canese, R | 1 |
| Carpinelli, G | 1 |
| Podo, F | 1 |
| Ferrari, AU | 1 |
| Hardt, SE | 1 |
| Tomita, H | 1 |
| Katus, HA | 1 |
| Sadoshima, J | 1 |
| Beĭshenkulov, MT | 1 |
| Kudaĭbergenova, NT | 1 |
| Baltabaev, TB | 1 |
| Takahashi, T | 1 |
| Tang, T | 1 |
| Lai, NC | 1 |
| Roth, DM | 1 |
| Rebolledo, B | 1 |
| Saito, M | 1 |
| Lew, WY | 1 |
| Clopton, P | 1 |
| Hammond, HK | 1 |
| Mansuy, P | 1 |
| Mougenot, N | 1 |
| Ramirez-Gil, JF | 1 |
| Bonnefont-Rousselot, D | 1 |
| Raillecove, F | 1 |
| Komajda, M | 1 |
| Lechat, P | 1 |
| Takeo, S | 1 |
| Elmoselhi, AB | 1 |
| Goel, R | 1 |
| Sentex, E | 1 |
| Wang, J | 1 |
| Su, JZ | 1 |
| Chen, SC | 1 |
| Wu, KG | 1 |
| Chen, DG | 1 |
| Rui, HB | 1 |
| Wang, XY | 1 |
| Wang, HJ | 1 |
| Yaoita, H | 1 |
| Sakabe, A | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Doi, M | 1 |
| Yano, M | 1 |
| Kobayashi, S | 1 |
| Kohno, M | 2 |
| Tokuhisa, T | 1 |
| Okuda, S | 1 |
| Suetsugu, M | 1 |
| Hisamatsu, Y | 1 |
| Ohkusa, T | 1 |
| Matsuzaki, M | 1 |
1 trial available for propranolol and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease.
Topics: Adrenergic beta-Antagonists; Digoxin; Diuretics; Dose-Response Relationship, Drug; Drug Administrati | 2003 |
19 other studies available for propranolol and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin.
Topics: Animals; beta-Arrestin 2; Blood Glucose; Diet, High-Fat; Fructose; Glucose; Heart; Insulin; Insulin | 2021 |
Effects of the administration of beta-blockers on ventricular remodeling induced by cigarette smoking in rats.
Topics: Adrenergic beta-Antagonists; Animals; Inhalation Exposure; Male; Models, Animal; Propranolol; Rats; | 2009 |
Amelioration of cardiac remodeling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Depression, Chemical; Electrocardiog | 2010 |
β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blotting, Northern; Ca(2+) Mg(2+)-ATPase; Dose-Respo | 2011 |
Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats?
Topics: Adrenergic Antagonists; Animals; Apoptosis; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dise | 2010 |
Combined blockade of β- and α₁-adrenoceptors in left ventricular remodeling induced by hypertension: beneficial or not?
Topics: Adrenergic Antagonists; Animals; Bisoprolol; Carbazoles; Carvedilol; Disease Models, Animal; Humans; | 2010 |
Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress.
Topics: Adrenergic beta-Antagonists; Animals; Antigens, CD; beta Catenin; Biomechanical Phenomena; Cadherins | 2010 |
Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca2+ signaling in rat.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Calcium Signaling; | 2011 |
Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomyopathies; Echocardiogr | 2012 |
Calcium dynamics in the failing heart: restoration by beta-adrenergic receptor blockade.
Topics: Adrenergic beta-Antagonists; Aniline Compounds; Animals; Blotting, Western; Calcium; Calcium Signali | 2003 |
Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded mice.
Topics: Animals; Aorta; Echocardiography; Hemodynamics; Hypertrophy, Left Ventricular; Magnetic Resonance Im | 2003 |
Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy.
Topics: Adenoviridae; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Atri | 2004 |
[Functional features of acute non-Q-wave myocardial infarction and the influence of pre-hospital treatment with propranalol, heparin and aspirin on the prognosis of the disease].
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Aspirin; Data Interpretation, Statistical; Elect | 2005 |
Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Apoptosis; Calcium; Cyclic AMP; Female; Gen | 2006 |
Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats.
Topics: Animals; Anti-Arrhythmia Agents; Heart Failure; Male; Muscle Contraction; Myocardial Infarction; Oxi | 2000 |
Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blotting, | 2000 |
Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |
Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Ascorbic Acid; Carbazoles; Cardi | 2002 |
Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Cardiac Pacing, Artificial; Diastole; Disease Models, | 2002 |